Teva's Austedo Franchise Drives 72% Year-Over-Year EPS Growth with Positive New Trial Data

The Quick Take

• Teva's EPS surged 72% year-over-year in Q1 2026, driven primarily by its Austedo/Austedo XR franchise
• Austedo, approved for tardive dyskinesia and Huntington's disease chorea, continues to gain prescriber adoption
• New positive clinical study data for Austedo XR adds forward revenue visibility and reduces competitive risk
• Teva's debt reduction trajectory and generic business stability support continued EPS expansion thesis

Teva Pharmaceutical delivered a standout Q1 2026 earnings performance, with earnings per share growing 72% year-over-year, anchored by the continued commercial expansion of its Austedo and Austedo XR products. Austedo, a deutetrabenazine formulation approved for tardive dyskinesia (TD) and Huntington's disease chorea, has emerged as Teva's flagship growth driver following years of balance sheet restructuring and generic portfolio optimization. The drug competes in a relatively underpenetrated market for TD, a movement disorder caused by long-term antipsychotic use, where treatment rates have historically been low despite a meaningful patient population.

New clinical study data released alongside the earnings report added forward earnings visibility by demonstrating continued efficacy and safety performance for the Austedo XR extended-release formulation, which offers a once-daily dosing advantage that has supported prescriber switching from the immediate-release version. For a company that spent several years managing a heavy debt burden following its 2016 Actavis Generics acquisition, the sustained growth of Austedo represents a meaningful transformation in Teva's revenue quality. The shift from a heavily generics-dependent model toward a branded specialty drug anchor has significantly improved Teva's earnings stability and margin profile.

Forward signals for Teva's investment case remain constructive. The continued growth of the Austedo franchise, declining interest expense from ongoing debt reduction, and stability in the global generic drug market combine to sustain a multi-year EPS expansion trajectory. Key risks include potential biosimilar or small-molecule competition in the TD treatment market and any regulatory headwinds for the branded portfolio. Investors will monitor prescriber trends for Austedo XR, pipeline progress for Teva's other specialty assets, and the company's ability to deploy free cash flow into debt paydown or selective business development activity that extends the branded revenue mix.

Synthesized from 2 sources — full coverage, sentiment breakdown, and forward signals below.